FDA Approves Pegvaliase for PKU in Teens | News

The U.S. Food and Drug Administration (FDA) has expanded the approval of PALYNZIQ® (pegvaliase-pqpz) to include adolescents aged 12 years and older with phenylketonuria (PKU). This marks the first enzyme substitution therapy authorized for this age group, offering a new treatment option for a challenging metabolic disorder. The approval, announced February 27, 2026, builds on the existing approval for adult patients and addresses a critical need for more effective PKU management during the often-difficult teenage years.

Understanding Phenylketonuria (PKU)

Phenylketonuria is a rare, inherited genetic disorder that affects how the body breaks down phenylalanine (Phe), an amino acid found in many foods. Individuals with PKU lack or have a deficiency in the enzyme phenylalanine hydroxylase (PAH), which is necessary to convert Phe into tyrosine. Without this conversion, Phe builds up in the blood, leading to potential neurological damage, intellectual disability, and other serious health problems if left untreated. The condition is typically detected through newborn screening programs, and management traditionally relies on a strict, lifelong diet severely restricting Phe intake.

PALYNZIQ: A New Approach to PKU Management

PALYNZIQ represents a different approach to PKU treatment. It’s an enzyme substitution therapy, meaning it provides the missing PAH enzyme to help break down Phe. Specifically, it uses a PEGylated version of the enzyme, designed to reduce Phe concentrations in the blood. This differs from the traditional dietary management, which focuses on limiting Phe intake. The medication comes with a Boxed Warning for anaphylaxis, a severe allergic reaction, requiring administration in a setting where anaphylaxis can be treated.

PEGASUS Trial: Evidence Supporting the Expansion

The FDA’s decision to extend the approval to adolescents was based on data from the PEGASUS study, a Phase 3 clinical trial. This multi-center, open-label, randomized controlled study evaluated PALYNZIQ’s safety and efficacy compared to diet alone in adolescents (ages 12 to under 18) with PKU who had poorly controlled blood Phe levels – greater than 600 µmol/L – despite existing management strategies. Results showed that adolescents receiving PALYNZIQ experienced a statistically significant reduction in blood Phe levels compared to those continuing diet alone. According to BioMarin, the manufacturer, 44.4% of patients in the PALYNZIQ arm reached Phe levels below guideline recommendations by the finish of the first part of the study. It’s crucial to note that the study was open-label, meaning both participants and researchers knew who was receiving the treatment, which could introduce bias. Further research will be needed to confirm these findings and assess long-term outcomes.

Adolescence: A Particularly Vulnerable Time for PKU Management

The approval specifically addresses the challenges of managing PKU during adolescence. As Dr. Stephanie Sacharow, Director of the Dr. Harvey Levy Program for PKU and Related Conditions at Boston Children’s Hospital, explained, this period is marked by increasing independence and academic pressures, making adherence to the restrictive PKU diet more difficult. Poor blood Phe control during these formative years can lead to adverse neurocognitive outcomes. The availability of a medication that may allow for a less restrictive diet, while still effectively lowering Phe levels, could significantly improve the quality of life for teenagers with PKU. Dr. Sacharow also noted that treatment adherence appears to be more successful in teens still living at home with family support.

What This Means for Patients and Families

This expanded approval offers a new therapeutic option for adolescents with PKU who struggle to maintain adequate Phe control with diet alone. It’s not a cure, and it doesn’t eliminate the need for dietary management entirely, but it may provide greater flexibility and improve metabolic control. However, it’s crucial to remember the risk of anaphylaxis and the need for administration in a setting equipped to manage such reactions. Patients and families should discuss the potential benefits and risks of PALYNZIQ with a qualified clinician to determine if it’s an appropriate treatment option. The medication is genotype-independent, meaning its effectiveness isn’t tied to the specific genetic mutation causing the PKU, potentially broadening its applicability.

Looking Ahead: Ongoing Research and Monitoring

The FDA approval is based on the PEGASUS trial data, but ongoing monitoring and further research are essential. The FDA will continue to monitor the safety and effectiveness of PALYNZIQ through post-market surveillance. Additional studies may be conducted to evaluate long-term outcomes, identify potential biomarkers for treatment response, and refine treatment protocols. The exclusivity end date for the approved indication is currently listed as “TBD” according to the FDA’s Orphan Drug Designations and Approvals database, meaning the period of market exclusivity has not yet been determined. This approval represents a significant step forward in PKU management, but continued vigilance and research are vital to optimize treatment and improve the lives of individuals living with this challenging condition.